Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
CNS Drugs
|
August 18, 2019
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
Basil T Darras, Michelle A Farrar, Eugenio Mercuri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 1, 2014
Immune reconstitution after allogeneic hematopoietic stem cell transplantation is associated with selective control of JC virus reactivation
Chen Sabrina Tan, Thomas A Broge, Long Ngo, et al.
Journal of Virology
|
May 6, 2011
Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome
Sarah Gheuens, Evelyn Bord, Santosh Kesari, et al.
Annals of Clinical and Translational Neurology
|
December 11, 2014
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
Tuan Dong-Si, Sandra Richman, Mike P Wattjes, et al.
Journal of Neurovirology
|
March 17, 2015
Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy
Tuan Dong-Si, Sarah Gheuens, Amy Gangadharan, et al.
Journal of Neuropathology and Experimental Neurology
|
October 17, 2013
Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study
Christian Wüthrich, Bogdan F Gh Popescu, Sarah Gheuens, et al.
The Lancet. Neurology
|
February 24, 2017
Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
Jacob Elkins, Roland Veltkamp, Joan Montaner, et al.
The Lancet. Haematology
|
August 21, 2022
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial
Andreas Glenthøj, Eduard J van Beers, Hanny Al-Samkari, et al.
Neurology
|
April 26, 2019
Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies
Basil T Darras, Claudia A Chiriboga, Susan T Iannaccone, et al.
The New England Journal of Medicine
|
April 13, 2022
Mitapivat versus Placebo for Pyruvate Kinase Deficiency
Hanny Al-Samkari, Frédéric Galactéros, Andreas Glenthøj, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
CNS Drugs
|
August 18, 2019
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
Basil T Darras, Michelle A Farrar, Eugenio Mercuri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 1, 2014
Immune reconstitution after allogeneic hematopoietic stem cell transplantation is associated with selective control of JC virus reactivation
Chen Sabrina Tan, Thomas A Broge, Long Ngo, et al.
Journal of Virology
|
May 6, 2011
Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome
Sarah Gheuens, Evelyn Bord, Santosh Kesari, et al.
Annals of Clinical and Translational Neurology
|
December 11, 2014
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
Tuan Dong-Si, Sandra Richman, Mike P Wattjes, et al.
Journal of Neurovirology
|
March 17, 2015
Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy
Tuan Dong-Si, Sarah Gheuens, Amy Gangadharan, et al.
Journal of Neuropathology and Experimental Neurology
|
October 17, 2013
Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study
Christian Wüthrich, Bogdan F Gh Popescu, Sarah Gheuens, et al.
The Lancet. Neurology
|
February 24, 2017
Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
Jacob Elkins, Roland Veltkamp, Joan Montaner, et al.
The Lancet. Haematology
|
August 21, 2022
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial
Andreas Glenthøj, Eduard J van Beers, Hanny Al-Samkari, et al.
Neurology
|
April 26, 2019
Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies
Basil T Darras, Claudia A Chiriboga, Susan T Iannaccone, et al.
The New England Journal of Medicine
|
April 13, 2022
Mitapivat versus Placebo for Pyruvate Kinase Deficiency
Hanny Al-Samkari, Frédéric Galactéros, Andreas Glenthøj, et al.
Page
of 3